These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1490199)

  • 1. von Willebrand factor as a marker of endothelial cell activation following BMT.
    Collins PW; Gutteridge CN; O'Driscoll A; Blair S; Jones L; Aitchison R; Kelsey SM; Chopra R; Goldstone A; Newland AC
    Bone Marrow Transplant; 1992 Dec; 10(6):499-506. PubMed ID: 1490199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).
    Zeigler ZR; Rosenfeld CS; Andrews DF; Nemunaitis J; Raymond JM; Shadduck RK; Kramer RE; Gryn JF; Rintels PB; Besa EC; George JN
    Am J Hematol; 1996 Dec; 53(4):213-20. PubMed ID: 8948657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of endothelial function in pediatric stem cell transplantation for acute leukemia.
    Luzzatto G; Cella G; Messina C; Randi ML; Sbarai A; Zanesco L
    Med Pediatr Oncol; 2003 Jan; 40(1):9-12. PubMed ID: 12426679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.
    Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Hiller E
    Bone Marrow Transplant; 1997 May; 19(9):909-14. PubMed ID: 9156265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease.
    Bazarbachi A; Scrobohaci ML; Gisselbrecht C; Marolleau JP; Mansi A; Brice P; Gorra P; Drouet L
    Nouv Rev Fr Hematol (1978); 1993 Apr; 35(2):135-40. PubMed ID: 8332449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
    Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
    Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial lesion in patients undergoing bone marrow transplantation.
    Richard S; Seigneur M; Blann A; Adams R; Renard M; Puntous M; Boiron JM; Amiral J; Reiffers J; Boisseau M
    Bone Marrow Transplant; 1996 Nov; 18(5):955-9. PubMed ID: 8932851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelium and bone marrow transplantation.
    Catani L; Gugliotta L; Vianelli N; Nocentini F; Baravelli S; Bandini G; Cirio TM; Tura S
    Bone Marrow Transplant; 1996 Feb; 17(2):277-80. PubMed ID: 8640179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
    Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activation of endothelium-dependent hemostatic factors following bone marrow transplantation].
    Tsakiris DA; Marbet GA; Tichelli A; Gratwohl A; Speck B
    Schweiz Med Wochenschr; 1995 Mar; 125(9):416-9. PubMed ID: 7892569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.
    Ferro D; Quintarelli C; Lattuada A; Leo R; Alessandroni M; Mannucci PM; Violi F
    Hepatology; 1996 Jun; 23(6):1377-83. PubMed ID: 8675154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
    Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
    Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hemostatic alterations following bone marrow transplantation: a prospective study.
    Vannucchi AM; Rafanelli D; Longo G; Bosi A; Guidi S; Saccardi R; Filimberti E; Cinotti S; Grossi A; Morfini M
    Haematologica; 1994; 79(6):519-25. PubMed ID: 7896209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII).
    Vischer UM; Emeis JJ; Bilo HJ; Stehouwer CD; Thomsen C; Rasmussen O; Hermansen K; Wollheim CB; Ingerslev J
    Thromb Haemost; 1998 Dec; 80(6):1002-7. PubMed ID: 9869174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.